SABS
SAB Biotherapeutics Inc
3.10$
-3.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -267.7% | 18.1% | 3.3% | -98.1% | -1,121.9% | -2,593.1% | – | |
| 9.4% | 1.0% | 2.7% | 13.8% | 167.3% | 362.4% | – | |
| 10.8% | 2.3% | 3.8% | 11.2% | 108.3% | 222.5% | – | |
| 10.8% | 2.3% | 9.5% | -32.4% | – | – | – | |
| -26.8% | -21.6% | 19.2% | -1.0% | 103.9% | -173.8% | – | |
| 17.7% | 23.0% | 18.0% | 9.1% | 8.8% | 25.5% | – | |
| -17.7% | -23.0% | -18.0% | -8.7% | -6.8% | -904.6% | – | |
| – | – | 0.0% | -23.1% | 0.0% | – | – | |
| -18.1% | -1.7% | -0.4% | -4.3% | -17.4% | -68.6% | – | |
| 107.0% | 16.3% | 59.0% | 4.4% | 2,982.3% | -88.7% | – | |
| -178.4% | 11.3% | 44.2% | -102.5% | 1,854.4% | -3,604.6% | – | |
| -285.4% | -4.9% | -14.7% | -107.2% | -1,130.7% | -2,618.6% | – |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.